GLAXO.NS Profit & Loss
Glaxosmithkline Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:36
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹3,251.72 Cr. | ₹3,453.71 Cr. | ₹3,749.21 Cr. | ₹3,821.67 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹100.66 Cr. | ₹122.59 Cr. | ₹145.93 Cr. | ₹145.36 Cr. | OtherIncome |
| Total Income | ₹3,352.38 Cr. | ₹3,576.30 Cr. | ₹3,895.14 Cr. | ₹3,967.03 Cr. | Income |
| Cost of Materials Consumed | ₹427.48 Cr. | ₹545.17 Cr. | ₹499.90 Cr. | ₹436.15 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹788.43 Cr. | ₹853.08 Cr. | ₹845.11 Cr. | ₹910.45 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹68.96 Cr. | ₹-63.72 Cr. | ₹45.85 Cr. | ₹4.46 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹594.99 Cr. | ₹624.39 Cr. | ₹579.70 Cr. | ₹607.25 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹1.81 Cr. | ₹1.80 Cr. | ₹1.31 Cr. | ₹2.73 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹65.77 Cr. | ₹69.68 Cr. | ₹66.79 Cr. | ₹66.44 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹567.57 Cr. | ₹586.10 Cr. | ₹601.29 Cr. | ₹554.16 Cr. | OtherExpenses |
| Total Expenses | ₹2,515.01 Cr. | ₹2,616.50 Cr. | ₹2,639.95 Cr. | ₹2,581.64 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹837.37 Cr. | ₹959.80 Cr. | ₹1,255.19 Cr. | ₹1,385.39 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹-0.97 Cr. | ₹-143.61 Cr. | ₹4.69 Cr. | ₹20.62 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹836.40 Cr. | ₹816.19 Cr. | ₹1,259.88 Cr. | ₹1,406.01 Cr. | ProfitBeforeTax |
| Tax Expense | ₹228.76 Cr. | ₹226.23 Cr. | ₹332.30 Cr. | ₹370.03 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹610.69 Cr. | ₹589.96 Cr. | ₹927.58 Cr. | ₹1,035.98 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹610.69 Cr. | ₹589.96 Cr. | ₹0.00 Cr. | N/A | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹36.05 | ₹34.83 | ₹54.52 | ₹54.52 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹36.05 | ₹34.83 | ₹54.76 | ₹54.76 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from GLAXO.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).